Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neuroendocrine Tumors 2Meningioma 1

Interventions

Hydroxyurea 4aldesleukin 3Magnetic Resonance Spectroscopy 3Imatinib Mesylate 3Everolimus 3Temozolomide 2Surveys and Questionnaires 2Surgical Procedures, Operative 2Radiotherapy, Intensity-Modulated 2Radiotherapy, Conformal 2Psychiatric Rehabilitation 2Proton Therapy 2Paclitaxel 2Laser Speckle Contrast Imaging 2Filgrastim 2Donepezil 2Cyclophosphamide 2Carmustine 2Bortezomib 2Bevacizumab 2Aminolevulinic Acid 290Y-octreotide, DOTA-Tyr(3)- 2vistusertib 1vatalanib 1trametinib 1tozuleristide 1temsirolimus 1sonidegib 1sargramostim 1ribociclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Meningioma × 64Cu-SARTATE × Clear all
NCT03936426 2020-04-20

Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATEâ„¢

Clarity Pharmaceuticals Ltd

Phase 1/2 Completed
5 enrolled
CNS

Meningioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡